Biokinetics Optimize Image Quality

MYOVIEW exhibits the four principal biokinetic properties essential to image quality

  • Prompt myocardial uptake and rapid blood, liver, and lung clearance 1-5
  • Proportional uptake to reveal reduced blood flow
    to ischemic regions 1,2,4,5
  • Good target-to-background ratio, minimizing interference from organs near the heart 3-5
  • Myocardial retention with little or no redistribution during window of image acquisition 2,3,5

Biokinetic advantages of MYOVIEW enhance image quality

  • Rapid clearance from the blood, liver, and lungs:
    • Optimizes heart visualization 3,5,6
    • Reduces artifacts from surrounding organs 2,4,6
  • High target-to-background ratio provides clearer images 3,5
  • Minimal redistribution improves image integrity, ensuring diagnostic confidence 6
  • Quality images available as early as 15 minutes and up to 4 hours postinjection

Biokinetic Properties Yield Quality Images Sooner

MYOVIEW:

  • Yields an extended window of time for imaging 3,5
  • Achieves high heart-to-liver ratios rapidly 3,4
  • Provides clearer images of the heart sooner 3,4
  • Allows early imaging of stress and rest images 3,5
  • The relationship between myocardial blood flow and tracer uptake has been studied in a canine model of coronary artery occlusion with pharmacologically induced hyperemia 5
  • Decreased myocardial extraction at high coronary flow rates is characteristic of all diffusible flow tracers, including thallium-201 7

In studying patients with known or suspected coronary artery disease, care should be taken to ensure continuous cardiac monitoring and the availability of emergency cardiac treatment. As with all injectable drug products, allergic reactions, and anaphylaxis may occur.
 
Pharmacologic induction of cardiovascular stress may be associated with serious adverse events, such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, and cerebrovascular events. Caution should be used when pharmacologic stress is selected as an alternative to exercise; it should be used when indicated and in accordance with the pharmacologic stress agent's labeling. The most common adverse reactions reported from post-marketing experience included rash, urticaria, abnormal vision, allergic reactions, and fever.

References: 1. MYOVIEW Prescribing Informatian. 2. Iskandrian AE, Verani MS. Nuclear imaging techniques. In: Tapai EJ, ed. Textbook of Cardiavascular Medicine. Philadelphia, PAc Lippincott-Raven; 1998:1367-1371. 3. Higley B, Smith FW, Smith T, etal. Technetium-99m-1 ,2-bis[bis(2-ethaxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med. 1993;34:30-38. 4. Munch G, Neverve J, Matsunari I, Schroter G, Schwaiger M. Myocardialtechnetium-99m-tetrafosmin and technetium- 99m-sestamibi kinetics in normal subjects and patients with coranary artery disease. J Nucl Med. 1997;38:428-432. 5. Jain D. Technetium-99m labeled myocardial perfusion imaging agents. Sem Nucl Med. 1999:29:221-236. 6. Jain D. Nuclear medicine agent brings speed ta cardiac imaging lineup. Adv Radiol Sci prof May 2000:34-35. 7. Glover DK, Ruiz M, Yang JY, Smith WH, Watson DD, Beller GA. Myocardial 99m-tetrafosmin uptake during adenasine-induced vasodilatation with either a critical or mild caronary stenosis: comparison with 210-TI and regional myocardial blood Row. Circulation. 1997;96:2332-2338.